Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung
Standard
Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. / Blonski, Katharina; Schumacher, Udo; Burkholder, Iris; Edler, Lutz; Nikbakht, Haleh; Boeters, Ina; Peters, Anja; Kugler, Christian; Horny, Hans-Peter; Langer, Martin; Wilhelm-Ogunbiyi, Karin; Witthohn, Klaus; Laack, Eckart.
In: ANTICANCER RES, Vol. 25, No. 5, 17.08.2005, p. 3303-7.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung
AU - Blonski, Katharina
AU - Schumacher, Udo
AU - Burkholder, Iris
AU - Edler, Lutz
AU - Nikbakht, Haleh
AU - Boeters, Ina
AU - Peters, Anja
AU - Kugler, Christian
AU - Horny, Hans-Peter
AU - Langer, Martin
AU - Wilhelm-Ogunbiyi, Karin
AU - Witthohn, Klaus
AU - Laack, Eckart
PY - 2005/8/17
Y1 - 2005/8/17
N2 - BACKGROUND: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant glycosylation, detected by lectin histochemistry, can predict outcome in some tumour entities. One such lectin is aviscumine (recombinant mistletoe lectin). Aviscumine has cytotoxic effects and can therefore be used as anti-tumour therapy.MATERIALS AND METHODS: Lectin histochemistry with aviscumine was performed on primary tumour sections from resected adenocarcinoma of the lung. Staining results were then correlated with the clinical course of the patients.RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival.CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.
AB - BACKGROUND: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant glycosylation, detected by lectin histochemistry, can predict outcome in some tumour entities. One such lectin is aviscumine (recombinant mistletoe lectin). Aviscumine has cytotoxic effects and can therefore be used as anti-tumour therapy.MATERIALS AND METHODS: Lectin histochemistry with aviscumine was performed on primary tumour sections from resected adenocarcinoma of the lung. Staining results were then correlated with the clinical course of the patients.RESULTS: Most of the adenocarcinomas (92.5%) bound aviscumine. Kaplan-Meier analysis revealed no correlation between aviscumine binding and progression-free survival or overall survival.CONCLUSION: These results suggest that for the selected group of patients with adenocarcinoma of the lung aviscumine binding activity can not serve as a prognostic factor. More strikingly, however, aviscumine binds to malignant cells in 92.5% of the patients. This is an indicator for the use of aviscumine as a possible target for tumour therapy.
KW - Adenocarcinoma
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Disease-Free Survival
KW - Female
KW - Glycosylation
KW - Histocytochemistry
KW - Humans
KW - Lung Neoplasms
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Plant Preparations
KW - Plant Proteins
KW - Recombinant Proteins
KW - Ribosome Inactivating Proteins, Type 2
KW - Toxins, Biological
M3 - SCORING: Journal article
C2 - 16101142
VL - 25
SP - 3303
EP - 3307
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 5
ER -